Compare PI & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PI | SRRK |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.6B |
| IPO Year | 2011 | 2018 |
| Metric | PI | SRRK |
|---|---|---|
| Price | $103.96 | $49.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $176.38 | $55.64 |
| AVG Volume (30 Days) | 348.2K | ★ 1.7M |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $122,633,000.00 | N/A |
| Revenue This Year | $4.26 | N/A |
| Revenue Next Year | $25.04 | $544.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $62.94 | $27.07 |
| 52 Week High | $247.06 | $51.63 |
| Indicator | PI | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 49.23 | 59.40 |
| Support Level | $103.98 | $41.07 |
| Resistance Level | $131.82 | N/A |
| Average True Range (ATR) | 5.32 | 2.21 |
| MACD | 1.69 | 0.51 |
| Stochastic Oscillator | 64.99 | 82.19 |
Impinj Inc operates a platform that enables wireless connectivity to everyday items by delivering each item's identity, location, and authenticity to business and consumer applications. Its platform includes endpoint integrated circuits (ICs) product, a miniature radios-on-a-chip, which attach to and identify their host items; and connectivity layer that comprises readers, gateways, and reader ICs to wirelessly identify, locate, authenticate, and engage endpoints via RAIN, as well as provide power to and communicate bidirectionally with endpoint ICs. Geographically, the company has a business presence in the Americas, Asia Pacific, Europe, Middle East and Africa, of which key revenue is derived from the operations in the Asia Pacific region.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.